Digoxin Toxicity

Cardiac Manifestations

The American College of Cardiology notes that typical arrhythmias include enhanced atrial, junctional, or ventricular automaticity (with ectopic beats or tachycardia) often combined with atrioventricular block 1, 2
Ventricular tachycardia that is fascicular or bidirectional in origin is highly suggestive of digoxin toxicity 1, 3
Severe digoxin overdose can cause hyperkalemia and cardiac standstill 1, 3

Gastrointestinal Manifestations

The European Society of Cardiology reports that anorexia, nausea, and vomiting are common gastrointestinal symptoms of digoxin toxicity 4

Neurological Manifestations

The American College of Cardiology states that changes in mentation/confusion are neurological manifestations of digoxin toxicity 1, 3
Visual disturbances (blurred or yellow vision) are also reported as neurological symptoms of digoxin toxicity 4

Diagnostic Considerations

The American College of Cardiology recommends that diagnosis is established by the combination of characteristic rhythm disturbances, ancillary symptoms (visual disturbances, nausea, changes in mentation), and elevated serum concentrations 1, 3
Overt digoxin toxicity is commonly associated with serum digoxin levels greater than 2 ng/mL, but toxicity may occur at lower levels 5, 6
Toxicity can occur even when serum concentration is within therapeutic range (0.5-1.2 ng/mL) 4

Risk Factors and Potentiating Conditions

The American College of Cardiology notes that hypothyroidism, hypokalemia, and hypomagnesemia are risk factors for digoxin toxicity 1, 3, 5
Renal dysfunction and advanced age are also risk factors for digoxin toxicity 1, 3, 5, 6
Concomitant medications that increase digoxin levels, such as amiodarone, clarithromycin, erythromycin, itraconazole, cyclosporine, verapamil, quinidine, propafenone, and dronedarone, can potentiate digoxin toxicity 4, 5, 6

Management Considerations

The American College of Cardiology recommends that for mild cases, medication should be discontinued, rhythm monitored, and normal serum potassium maintained 1, 3
For severe intoxication (serum digoxin concentrations >4 ng/mL with serious arrhythmias), digoxin-specific Fab antibodies should be administered 1, 3
Intravenous magnesium is often administered if ventricular arrhythmias are present 1, 3
Temporary pacing may be needed for atrioventricular block or asystole 1, 3

Management of Elevated Digoxin Levels

Patient Risk Factors

Advanced age (>70 years) and low lean body mass are risk factors that may potentiate digoxin toxicity, according to the American Heart Association guidelines 7
Concomitant medications such as amiodarone, clarithromycin, erythromycin, itraconazole, cyclosporine, verapamil, quinidine, propafenone, and dronedarone can increase digoxin levels, as recommended by the American College of Cardiology 7

Resumption of Therapy

If digoxin therapy must be continued after levels normalize, the American College of Cardiology recommends using lower doses (0.125 mg daily or every other day) for patients with risk factors 7
When reinitiating therapy, the American Heart Association suggests avoiding loading doses to minimize the risk of toxicity 8

Administering IV Digoxin to a Patient with Hypokalemia

Risks of Digoxin Administration with Hypokalemia

Administering digoxin 125 mcg IV to a patient with a potassium level of 3.3 mEq/L significantly increases the risk of digoxin toxicity and potentially life-threatening cardiac arrhythmias 9
Hypokalemia (potassium level of 3.3 mEq/L) significantly increases the risk of digoxin toxicity, even when serum digoxin levels are within the therapeutic range 9, 10

Management Algorithm

Correct hypokalemia before administering digoxin, according to the American Heart Association, by administering oral or intravenous potassium to achieve a serum level between 4.0-5.5 mEq/L 9, 10
If digoxin must be administered urgently, reduce the dose to 0.125 mg or less, as recommended by the American College of Cardiology, and monitor cardiac rhythm continuously 9

Management of Digoxin Toxicity

Introduction to Management

The American College of Cardiology and Circulation recommend digoxin-specific antibody fragments (digoxin-Fab) as the first-line treatment for digoxin toxicity with life-threatening manifestations, including serious arrhythmias, hyperkalemia, or hemodynamic compromise 11, 12

Ineffective Treatments

The American Heart Association suggests that hemodialysis, hemofiltration, hemoperfusion, or plasmapheresis are not recommended for digoxin toxicity 11

Management of Chronic Digoxin Toxicity

Initial Management and Severity Stratification

The American Heart Association recommends immediately discontinuing digoxin, correcting electrolyte abnormalities, and administering digoxin-specific Fab antibody fragments for life-threatening manifestations, including sustained ventricular arrhythmias, advanced AV block, asystole, or severe hyperkalemia, with a Class I recommendation and Level of Evidence A 13
For mild toxicity, discontinue digoxin immediately and initiate continuous cardiac rhythm monitoring, with the goal of restoring serum potassium to >4.0 mEq/L, ideally 4.0-5.5 mEq/L, through oral or intravenous supplementation, as recommended by the American College of Cardiology 13, 14
Correct hypomagnesemia and ensure adequate oxygenation, as suggested by the American Heart Association 13
Administer digoxin-specific Fab antibody fragments immediately for severe toxicity, with response typically occurring within 30 minutes to 4 hours, and a survival rate of 54% in severely intoxicated patients presenting with cardiac arrest, according to the American College of Cardiology 13, 14

Diagnostic Confirmation and Risk Factors

The diagnosis of digoxin toxicity requires the combination of characteristic arrhythmias, gastrointestinal symptoms, neurological symptoms, and elevated serum digoxin concentration, typically >2 ng/mL, as stated by the American Heart Association 13, 15
Monitor closely and maintain lower digoxin levels in patients with hypokalemia, hypomagnesemia, or hypothyroidism, renal dysfunction, advanced age, or low lean body mass, and drug interactions, as recommended by the American College of Cardiology 13, 15

Treatment and Management

Magnesium sulfate is reasonable for ventricular arrhythmias, with a Class IIa recommendation, as suggested by the American Heart Association 13, 14
Temporary cardiac pacing is reasonable for symptomatic bradyarrhythmias or heart block, according to the American College of Cardiology 13
Lidocaine or phenytoin should NOT be used for severe digoxin toxicity, with a Class III recommendation, as stated by the American Heart Association 13, 14
Hemodialysis, hemofiltration, or plasmapheresis are ineffective for digoxin removal, except in cases of life-threatening hyperkalemia in massive overdose, with a Class IIb recommendation, as suggested by the American College of Cardiology 13, 14

Post-Treatment Monitoring and Reinitiating Digoxin Therapy

Digoxin concentration monitoring is unreliable after Fab antibody administration, and monitoring for rebound toxicity and side effects of Fab therapy is necessary, as recommended by the American Heart Association 13
If digoxin must be restarted after toxicity resolves, use lower doses, target serum concentration of 0.5-0.9 ng/mL, and avoid loading doses, as suggested by the American College of Cardiology 15

Management of Asymptomatic Patient with Elevated Digoxin Levels

Immediate Management and Monitoring

The American College of Cardiology recommends Digibind administration for sustained ventricular arrhythmias or ventricular fibrillation, with a strength of evidence based on clinical guidelines 16
The presence of a permanent pacemaker is protective in this scenario, as it eliminates concern about symptomatic bradyarrhythmias or heart block, according to the European Heart Journal and European Journal of Heart Failure 16, 17

Special Considerations for Digoxin Therapy

The American College of Cardiology specifies that Digibind should only be administered for life-threatening manifestations, such as progressive bradyarrhythmias or heart block causing hemodynamic compromise, with a strength of evidence based on clinical guidelines 16
If digoxin therapy must be restarted, the European Journal of Heart Failure recommends using a significantly lower maintenance dose and targeting a therapeutic serum concentration of 0.5-0.9 ng/mL, with a strength of evidence based on clinical studies 16

Monitoring and Follow-Up

The European Heart Journal and European Journal of Heart Failure recommend monitoring cardiac rhythm continuously for at least 24-48 hours after discontinuation and rechecking digoxin level in 24-48 hours to confirm declining trend, with a strength of evidence based on clinical studies 16, 17

Calcium and Digoxin Toxicity

Mechanism and Risk Factors

Enhanced automaticity develops in atrial, junctional, or ventricular tissue, often combined with atrioventricular block, in digoxin-treated patients with elevated calcium levels, according to the European Heart Journal 18
The European Society of Cardiology identifies hypercalcemia as one of several key risk factors for digoxin toxicity, which can occur even when serum digoxin concentrations are within the therapeutic range 18
Hypokalemia, hypomagnesemia, and hypercalcemia form a triad of electrolyte disturbances that sensitize the myocardium to digoxin, as noted by the European Society of Cardiology 18
Other potentiating factors include renal dysfunction, advanced age, hypothyroidism, hypoxia, acidosis, and myocardial ischemia, as identified by the European Society of Cardiology 18

Management

Maintaining serum potassium between 4.0-5.5 mEq/L and correcting hypomagnesemia is crucial, as these electrolyte abnormalities compound the risk of digoxin toxicity, according to the European Heart Journal 18

Azithromycin and Steroid Interaction with Digoxin

Introduction to Azithromycin-Digoxin Interaction

The American College of Cardiology (ACC) and American Heart Association (AHA) list azithromycin as a drug that interacts with digoxin through P-glycoprotein inhibition, which can elevate serum digoxin concentrations and increase the risk of digoxin toxicity 19, 20
This interaction can increase the risk of digoxin toxicity, even when digoxin levels remain within the therapeutic range, and requires careful monitoring of digoxin levels and close observation for signs of toxicity 21
The combination of azithromycin and digoxin is not contraindicated but requires heightened vigilance, especially in patients with additional risk factors such as age >70 years, renal impairment, low lean body mass, hypokalemia, or hypomagnesemia 19

Required Monitoring and Dose Adjustment

The American College of Cardiology recommends checking baseline digoxin level before starting azithromycin and rechecking 24-48 hours after completing the Z-pak course, with a target therapeutic digoxin range of 0.5-0.9 ng/mL 21
Patients should be monitored continuously for signs of digoxin toxicity, including cardiac manifestations, gastrointestinal symptoms, and neurological symptoms, and the digoxin dose should be empirically reduced by 25-50% during the 5-day azithromycin course if the patient has additional risk factors 21
Risk factors that compound toxicity risk include age >70 years, renal impairment, low lean body mass, hypokalemia, hypomagnesemia, and hypothyroidism, and these patients should be closely monitored 19, 21

Corticosteroids and Digoxin Interaction

Corticosteroids do not directly alter digoxin pharmacokinetics through P-glycoprotein or CYP450 pathways, but can indirectly increase digoxin toxicity risk through electrolyte disturbances 19
Corticosteroids can cause hypokalemia and hypomagnesemia, which potentiate digoxin's cardiac effects even at therapeutic serum levels, and serum potassium and magnesium levels should be maintained within normal ranges throughout steroid therapy 19

Definitive Management of Life‑Threatening Digoxin Toxicity

Indications for Digoxin‑Fab Administration

The American Heart Association gives a Class I recommendation to administer digoxin‑specific antibody fragments (digoxin‑Fab) immediately in patients with life‑threatening digoxin toxicity, such as cardiac arrest or asystole. 22

Efficacy and Expected Clinical Response

Dysrhythmia typically resolves within 30–45 minutes after digoxin‑Fab administration in most patients. Class I evidence (AHA). 22
Observational studies report response rates of 50–90 % following digoxin‑Fab treatment. Class I evidence (AHA). 22
Even among patients who present with cardiac arrest, the survival rate after digoxin‑Fab is approximately 54 %. Class I evidence (AHA). 22

Temporizing Measures While Awaiting Digoxin‑Fab

Atropine may be used for bradydysrhythmias as a Class IIb option. (AHA) 22
Temporary cardiac pacing is a reasonable bridge therapy, but it carries a 36 % complication rate and may require higher-than‑normal pacing currents. (AHA, Class IIb) [22][23]
Lidocaine or phenytoin can be employed for ventricular dysrhythmias until digoxin‑Fab is available, also a Class IIb recommendation. (AHA) 22

Extracorporeal Therapies That Are Ineffective

Hemodialysis provides no benefit for digoxin removal and is assigned a Class III recommendation (AHA). 22
Hemofiltration, hemoperfusion, and plasmapheresis are similarly ineffective because digoxin’s large volume of distribution (5–10 L/kg) limits extracorporeal clearance. (AHA, Class III) [22][24]

Clinical Pitfalls and Diagnostic Considerations

Toxicity can occur at digoxin concentrations < 2 ng/mL when accompanied by electrolyte disturbances (hypokalemia, hypomagnesemia), hypothyroidism, or renal dysfunction; therefore, “therapeutic” serum levels do not exclude toxicity. (AHA, Class IIa) [25][26]